Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

1.36
-0.0400-2.86%
Post-market: 1.34-0.0199-1.46%17:51 EDT
Volume:22.33K
Turnover:30.46K
Market Cap:4.17M
PE:-0.15
High:1.39
Open:1.35
Low:1.34
Close:1.40
Loading ...

Sonnet Biotherapeutics Holdings Inc expected to post a loss of $5.52 a share - Earnings Preview

Reuters
·
11 Dec 2024

Sonnet BioTherapeutics announces $3.9M registered direct offering

TIPRANKS
·
10 Dec 2024

Sonnet Biotherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
10 Dec 2024

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
10 Dec 2024

Sector Update: Health Care Stocks Edge Higher Monday Afternoon

MT Newswires Live
·
10 Dec 2024

Sonnet BioTherapeutics Says Phase 1 Trial of SON-1010 Shows Partial Tumor Response, Disease Stabilization

MT Newswires Live
·
09 Dec 2024

Sonnet Biotherapeutics Holdings Inc - Update on Safety at Mtd Expected in Q1 2025

THOMSON REUTERS
·
09 Dec 2024

Sonnet Biotherapeutics Announces Topline Safety Data Following Successful Completion of Son-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

THOMSON REUTERS
·
09 Dec 2024

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

GlobeNewswire
·
09 Dec 2024

Sonnet BioTherapeutics announces publication on SON-1010 development

TIPRANKS
·
04 Dec 2024

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

GlobeNewswire
·
12 Nov 2024

Sonnet BioTherapeutics Prices $5 Million Public Offering; Shares Jump

MT Newswires Live
·
07 Nov 2024

Sonnet BioTherapeutics prices $5M at-the-market offering

TIPRANKS
·
07 Nov 2024

Sonnet Biotherapeutics Holdings Inc - Combined Offering Price of $4.50 per Share and Warrant

THOMSON REUTERS
·
07 Nov 2024

Sonnet Biotherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
07 Nov 2024

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
07 Nov 2024

Sonnet BioTherapeutics Receives US Patent for 2 Immunotherapeutic Drug Candidates

MT Newswires Live
·
06 Nov 2024

BRIEF-Sonnet Biotherapeutics Announces Issuance Of US Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates

Reuters
·
06 Nov 2024

Sonnet Biotherapeutics Announces Issuance of U.S. Patent Covering a Variant Il-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates

THOMSON REUTERS
·
06 Nov 2024

Sonnet Biotherapeutics Holdings Inc - Patent Term Effective Until June 2044

THOMSON REUTERS
·
06 Nov 2024